


# A new future for R&D?

Measuring the return from pharmaceutical innovation 2017

R&D returns **continue to fall** for the large cap biopharma original cohort




Cost to **bring an asset to market** has increased to record levels in 2017 for the large cap biopharma original cohort




Projected **peak sales per asset** increase by 18% in 2017 for the large cap biopharma original cohort



Fewer Phase III trials starting in the past year sees a decline in **number of late-stage assets**



Returns for the extension cohort of mid-tier biopharma companies increased in 2017



Extension cohort of mid-tier biopharma companies face 50% more costs, since 2013, to **bring an asset to market**



\$1.034 billion

\$1.982 billion

\$2.173 billion

Projected peak sales per asset have increased to **blockbuster levels** in 2017 for our extension cohort of mid-tier biopharma companies



A digital remedy for R&D productivity



**Deloitte.**

Deloitte Centre for Health Solutions

This publication has been written in general terms and does not constitute professional advice before acting or relying thereon. Deloitte LLP accepts no liability for any loss caused to any person acting or relying thereon as a result of any errors in this publication.

Deloitte LLP is a limited liability partnership registered in England and Wales with registered number 02938433 and is registered office at 1 New Street Square, London EC4A 3DF, United Kingdom.

Deloitte LLP is the United Kingdom affiliate of Deloitte 1906, LLC a member firm of Deloitte Touche Tohmatsu Limited, a UK limited company limited by guarantee (DTTL), DTTL and each of its member firms are legally separate and independent entities. DTTL and Deloitte 1906, LLC do not provide services to clients. Please see www.deloitte.com/uk for more information about our global network of member firms.

© 2017 Deloitte LLP. All rights reserved.

Designed and produced by The Creative Studio at Deloitte, London, UK 2017